24 April 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan University
Fareedi Mukram Ali
1ABEFG*, Ghassan M. Al-Iryani 23ABCEF, Khurshid A. Mattoo 4BCDEF, Mohammed Mousa H. Bakri 1ADEF, Ahmed Shaher Alqahtani 1ABEF, Somaih Abdullah Alasiri 5CDEF, Atheer Othman Hakami 6ADEF, Farheen Ustad 7CDEG, Hanan G. Shanab 7ACDEG, Khalid A. Al-Hamad 7ACDEG, Turki F. Almutairi 7ACDEG, Imran Khalid8CDEF
DOI: 10.12659/MSM.943884
Med Sci Monit 2024; 30:e943884
Table 2 Comparative differences in sex in prevalence of 4 commonly encountered medical comorbidities.
| Comorbidity type | Malen=300 (%) | Femalen=340 (%) | Combined prevalenceN=640 (%) | P value | |
|---|---|---|---|---|---|
| Endocrine (7.03%) | Diabetes mellitus (type I, II) | 20 (6.66) | 10 (2.94) | 30 (4.68) | .0334 (♂)* |
| Thyroid conditions | 5 (1.67) | 9 (2.64) | 14 (2.18) | 0.041 (♀)* | |
| Addison disease | 0 (0.00) | 1 (0.29) | 1 (0.15) | 0.000 (♀)* | |
| Cardiovascular (6.71%) | Hypertension | 14 (4.67) | 8 (2.35) | 22 (3.43) | 0.041(♂)* |
| Ischemic heart diseases | 7 (2.33) | 4 (1.17) | 11 (1.71) | 0.269 | |
| Hypotension | 1 (0.33) | 4 (1.17) | 5 (0.78) | 0.012 (♀)* | |
| Cardiac defects | 3 (1.00) | 1 (0.29) | 4 (0.46) | 0.078 | |
| Heart failure | 1 (0.33) | 0 (0.00) | 1 (0.15) | 0.000(♂)* | |
| Respiratory (4.53) | Bronchial asthma | 10 (3.33) | 7 (2.05) | 17 (2.65) | 0.258 |
| Chronic obstructive pulmonary disease | 1 (0.33) | 0 (0.00) | 1 (0.15) | 0.055 | |
| Miscellaneous | 4 (1.33) | 7 (2.05) | 11 (1.71) | 0.197 | |
| Hematological (3.44%) | Anaemia | 3 (1.00) | 6 (1.76) | 9 (1.40) | 0.025 (♀)* |
| Sickle cell | 5 (1.67) | 1 (0.29) | 6 (0.93) | 0.034 (♂)* | |
| Bleeding disorder | 5 (1.67) | 2 (0.58) | 7 (1.09) | 0.641 | |
| Symbols: ♂ – male; ♀ – female. Medical disorder categorization: 1=unstable angina, ST-segment and non-ST-segment elevation myocardial infarction, unspecified myocardial infarction; 2=rheumatic heart disease, valve replacements/previous endocarditis/hypertrophic cardiomyopathy; 3=hypothyroidism, hyperthyroidism, hypoparathyroidism; 4=tuberculosis, chronic bronchitis, emphysema, occupational lung disease, pulmonary hypertension. * Significant value at ≤0.05. When value obtained is 0 then the results will be infinity, and if the expected is actually 0 and the observed is not 0, the chi-square value would be infinity. | |||||